Sciton Launches diVa™; A Breakthrough Hybrid Fractional Laser for the Treatment of Vaginal Tissue

Sciton Forms New Business Unit and Launches diVa™ January 2016

Long known for providing a suite of best-in-class energy-based technologies on its singular expandable platform, the JOULETM, Sciton realized the need to expand its applications for treating women’s health because the majority of end patients are women going through various life milestones who would like to address health as well as aesthetic issues.

“As we develop our next generation of products, we regularly correspond with long-time users and recognize the need to apply our existing technologies to this particular space. Women have unique feminine issues that refined energy-based solutions can address, and it clearly makes sense for us to complement our current portfolio with a new suite of products focused on women,” said CEO Jim Hobart.

Sciton is also premiering its first product for the improvement of vaginal tissue. diVa, the first Hybrid Fractional Laser (HFLTM) for laser vaginal therapy, will be launched January 2016. diVa utilizes the revolutionary HFL technology developed for HaloTM, the world’s first and only hybrid fractional laser, to provide independent levels of ablation and coagulation, as well as varying levels of density. This allows the provider to customize the treatment based on the patient’s desired results.

Speaking on the need in the marketplace for a laser like diVa, Dr. Lionel Meadows, Fellow of the American College of Obstetrics and Gynecology, said, “Many patients young and old ask me daily if there is a nonsurgical, non-hormonal solution to improve the quality of their vaginal tissue. I can now recommend diVa.”

diVa is safe and suitable for women of all ages who may be interested in a resurfacing treatment to improve the quality of their vaginal tissue. The ergonomic, automated design of the hand-piece allows for a full treatment of the vaginal canal in approximately three to five minutes, with little to no discomfort to the patient and increased efficiency for the healthcare provider. “With diVa, physicians have an innovative way to treat feminine health. We’re excited to share the new features in diVa that exhibit Sciton’s commitment to excellence in resurfacing technology. This product uniquely incorporates High Precision Automation (HPA), using a refined motorized control system for the provider to deliver very fast, consistent, and predictable treatments for every patient. Additionally, we designed a single-use Strengthened Quartz Dilator (SQD) to be used with each patient, which eliminates the risk of cross-contamination and shortens downtime between treatments,” said President Dan Negus.

diVa is available on the JOULE platform, which offers multiple modules to treat a wide range of indications. Visit Sciton at booth #300 at AACS or www.sciton.com/diva to learn more about diVa.

ABOUT SCITON: Sciton is committed to providing best-in-class laser and light solutions for medical professionals who want superior durability, performance and value. Sciton offers high-quality medical devices for laser-assisted lipolysis, fractional and full-coverage skin resurfacing, hair removal, phototherapy, wrinkle reduction, treatment of vascular and pigmented lesions, scar reduction, and acne. For more information, and a complete listing of Sciton systems, visit www.Sciton.com. Like Sciton on Facebook at www.facebook.com/ScitonInc and follow Sciton on LinkedIn at www.linkedin.com/company/sciton.

First Diva practice announced in Michigan:  Sciton is pleased to announce that double board- certified cosmetic surgeon, Dr Gregory Roche will be the first physician to offer the Diva treatment to his patients in Michigan.  Dr Roche has a 30 year career providing outstanding clinical outcomes to his patients as well as being a pioneer in the region with laser and light based devices.  Dr Roche has worked beside the Diva lead clinical investigator, Dr Chad Deal to learn advanced techniques and will continue to be one of the leaders in future clinical trials.  You can learn more about Dr Roche and his practice at:

http://www.drroche.com.